mGlu7 Receptors , 0 Comments

For over one decade Glycoproteins IIb/IIIa inhibitors (GPI) have been administered to prevent coronary artery thrombosis. of bleeding vascular complications and thrombocytopenia. The clinical and ecomomic burden of major bleeding and thrombocytopenia is usually substantial. The ACUITY trial has initiate a new debate regarding the efficacy and safety of GPI. Selective Alosetron “patient-tailored” use of

Read More